Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO4995819 · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO4995819 15 mg | EXPERIMENTAL | - |
| RO4995819 30 mg | EXPERIMENTAL | - |
| RO4995819 5 mg | EXPERIMENTAL | - |
| RO4995819 capsule | EXPERIMENTAL | - |
| RO4995819 tablet | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| RO4995819 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | matching placebo to RO4995819 oral once daily for 6 weeks |
| RO4995819 | DRUG | 5 mg oral once daily for 6 weeks |
| activated charcoal | DRUG | orally 3 times daily, Days 1-7 |
| citalopram | DRUG | multiple oral doses, Days 1-16 |
Inclusion Criteria: * Adult patients, 18-65 years of age * Major depression disorder without psychotic features * Inadequate response to current, ongoing antidepressant treatment as defined by protocol * Having at least one but no more than 2 antidepressant treatment trial failures * Body mass inde...
Top 20 of 29 competitors
RO4995819 is an investigational small molecule being studied for Major Depressive Disorder and in healthy volunteer trials. It is developed by Roche Holding AG (ticker: RHHBY). The drug is currently in Phase 1 clinical development, with all four completed trials conducted in healthy volunteers.
RO4995819 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored four Phase 1 clinical trials of the drug, all of which have been completed. The trials were conducted in France and the United States.
RO4995819 is in Phase 1 clinical development. All four of its clinical trials are Phase 1 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities. It is being studied for Major Depressive Disorder and in healthy volunteer trials.
RO4995819 has been studied in four completed Phase 1 trials: NCT01367756 (combination with citalopram in healthy volunteers), NCT01409369 (effect of activated charcoal on pharmacokinetics), NCT01457664 (healthy elderly volunteers), and NCT01901159 (bioavailability and safety). All trials enrolled healthy volunteers.
RO4995819 is the sole name provided for this investigational drug. No alternative names have been identified in the available information. The drug is being developed by Roche Holding AG and is in Phase 1 clinical trials for Major Depressive Disorder and healthy volunteer studies.